Batch 001 - Live Allocation

3/100 SoldQ4 launch pricing · ends 31 Dec

Vivre Labs

Institutional Longevity

Catalogue
Single-vial Blends · one injection
Clinical Details

- Peptides -

- Single-vial Blends -

- Goals -

- Clinical Reference -

- Guides -

- Integrity -

◇ Compound Reference

NEUROIMMUNE PEPTIDEInvestigationalPopular · Neuroimmune

VIP

Vasoactive Intestinal Peptide · 10mg

Status

Investigational

Route

SubQ / nebulized

Half-life

Very short plasma half-life

Class

Vasoactive peptide

MechanismVPAC Receptor Agonism

Cohort16 active prescriptions

Educational reference only - not a prescription or dosing recommendation. Some compounds are investigational or used off-label; suitability is a question for your own doctor. See Informed Consent & Disclaimer.

V-Series Member

$85.50 USD/vial

À-la-carte: $90 USD/vial · Save 5%

Q4 launch pricing until 31 Dec · regular $100 USD/vial from 1 Jan

Vials per allocation

Member total (1×)$85.50

À-la-carte total$90

Flat per-vial pricing. International shipping $35, free on orders of $250 or more.

What this is

Systemic immunomodulatory and neuroprotective peptide. Applications in chronic inflammatory conditions and cognitive support.

Vasoactive Intestinal Peptide · 10mg per vial · lot-tested.

◇

Janoshik Verified

HPLC + MS purity, every batch

Independent third-party lab

⬡

COA Per Batch

Lot-level certificates published

Labeled vs actual mg disclosed

⊙

Lot-Tested

Every lot, independent lab

Report and verification code per lot

Used inV-Series

V-05

Calm - Inflammation & Gut

Popular · Immune & Inflammation

VIP · Neuroimmune Peptide

◆ Certificate of Analysis · VIP

JANOSHIK ANALYTICALHPLC + MS · Independent third-party

Lot testing in progress. The independent lab report for this VIP lot will be published here, with its verification code, as soon as it is back.

◉

Clinical Overview

VIP

Vasoactive Intestinal Peptide is a 28-amino-acid neuropeptide widely distributed throughout the central and peripheral nervous systems. Functions as a neurotransmitter, hormone, and immunomodulator.

❤

Vasodilation

Activates VPAC receptors driving vasodilation.

◈

Immune Modulation

Anti-inflammatory and immune-modulating activity.

❖

Neuroprotection

Neuroprotective effects in preclinical models.

◈

Mechanism

How It Works

Activates VPAC1 and VPAC2 receptors. Drives vasodilation, modulates immune cell activity, and exhibits neuroprotective and anti-inflammatory effects.

Particularly relevant in chronic inflammatory and respiratory conditions.

⊞

Technical Profile

Measurable Properties

Class	Vasoactive intestinal peptide (28 aa)
Mechanism	VPAC1/VPAC2 receptor signalling - characterised physiologically
Terminal half-life	Very short - minutes (plasma)
Metabolism	Rapid enzymatic degradation
Evidence base	Mechanism well-described; therapeutic use investigational
Regulatory status	Not a broadly approved therapy; research use only

Certificate of Analysis (per batch)

Analytical method: UHPLC-MS. Batch COA available on request - link to be populated per shipment.

COA link - pending per batch

Receptor pharmacology characterised; therapeutic use investigational. Educational only.

Clinical Literature

Peer-Reviewed References

Vasoactive Intestinal Peptide Reduces Apoptosis and Neurodegeneration in an Animal Model of Retinal Ischemia

Maugeri G, D'Amico AG, Magrì B, et al. · 2019 · PMC / Pharmaceuticals 2019

▾

Findings

Preclinical study using topically-administered VIP conjugated with a TAT cell-penetrating peptide (VIP-TAT) in a rat bilateral common carotid artery occlusion (BCCAO) model of ischemic retinal degeneration. Reported preservation of retinal cell counts and layer thickness versus untreated ischemia controls, via PAC1/VPAC receptor signalling. Note: in vivo rat model, retinal-specific endpoint, not a human outcome trial. The paper itself notes VIP shows ~10× lower potency than its sister peptide PACAP in equivalent models - informative context for interpretation.

View on publisher ↗

Therapeutic Use of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) and VIP for Retinal Neuroprotection

Werling D, Reglodi D, Banks WA, et al. · 2019 · Journal of Clinical Medicine 2019;8(8):1146

▾

Findings

Review article on the PACAP/VIP family for retinal and CNS neuroprotection. Compiles preclinical evidence across multiple animal models of ischemic, glaucomatous, and inflammatory retinal damage. Useful for understanding the broader VIP receptor-pathway literature, but not human outcome evidence. The review identifies the central translational gap: mechanism is well-characterised, clinical trials in humans are not.

View on publisher ↗

VIP is a real endogenous 28-amino-acid neuropeptide with substantial preclinical and mechanistic evidence (PAC1/VPAC receptor signalling, anti-inflammatory action, ADNP upregulation, retinal neuroprotection in BCCAO models). Outside its FDA-approved use as a pharmaceutical aid in specific endocrine testing contexts, robust controlled human outcome trials for nootropic or neuroprotective indications do not exist. Its preclinical-only evidence class and roughly 10× lower potency relative to PACAP are stated here.

◇

Clinical Applications

Indications

Chronic inflammatory conditions
CIRS (chronic inflammatory response syndrome)
Mold-related illness research
Sarcoidosis adjunct

⊙

Pharmacokinetics

Half-Life & Duration of Action

Half-life is how long a compound stays at active plasma concentration in your body. Most peptides in this catalogue have short plasma half-lives - they clear from your bloodstream within hours, sometimes minutes. The long-half-life compounds in this catalogue are the approved-class incretins (Tirzepatide, Semaglutide, Retatrutide), which are designed for once-weekly dosing - that's the molecular engineering choice that makes weekly dosing work.

Plasma Half-Life

Very short plasma half-life (minutes). Biological effects via receptor activation persist longer through downstream signaling cascades.

Why this matters for you

If you don't tolerate a compound or need to discontinue a protocol, short-half-life peptides are out of your bloodstream within hours - not days or weeks. That said, the biological effects they initiate (tissue repair signalling, mitochondrial signalling, gene expression changes) often persist longer than the peptide itself, through downstream cellular cascades. This is normal peptide pharmacology and is important context - the molecule clears fast, but the biology takes longer to wind down.

Evidence Base

Specialized clinical use, primarily in CIRS / mold illness practices.

Dosing protocols, administration frequency, and titration schedules are not published on these public pages.

▣

Featured In

V-Series Protocols Including VIP

◎

Commonly Paired

Compounds Often Paired With VIP

Clinical co-allocation patterns observed in Vivre's allocation history. Pairings are not prescriptions.

Cytoprotective Peptide

BPC-157

Base Form · 5mg

◆ neuroimmune + repair

VIP's systemic immunomodulatory action pairs with BPC-157 in protocols addressing chronic inflammatory conditions where tissue repair is also indicated. Both compounds appear in Vivre's V-05 inflammatory-resolution protocol.

View BPC-157 detail →

FOR CUSTOMERS

Mixing guide and dosage calculator

Unlocks once you order VIP: step-by-step mixing with illustrations, storage, and a calculator that converts any dose to syringe units at your vial strength.

READY TO PROCEED

Start with the Biological Audit

VIP is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.

$85.50 USD/vial

VIP · Member rate